title: Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.
authors.affiliation: Doheny Eye Institute/Los Angeles County and USC-LAC Medical Center, USA.
authors.forename: Jonathan C
authors.initials: JC
authors.lastname: Song
authors.forename: Peter J
authors.initials: PJ
authors.lastname: McDonnell
authors.forename: Erlinda M
authors.initials: EM
authors.lastname: Gordon
authors.forename: Frederick L
authors.initials: FL
authors.lastname: Hall
authors.forename: W French
authors.initials: WF
authors.lastname: Anderson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003318:Corneal Opacity / Q000628:therapy*; D056746:Cyclin G; D056766:Cyclin G1; D016213:Cyclins / Q000235:genetics* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D005822:Genetic Vectors; D006801:Humans; D008297:Male; D008875:Middle Aged; D012190:Retroviridae
chemical_list: C534702:CCNG1 protein, human; D056746:Cyclin G; D056766:Cyclin G1; D016213:Cyclins